Abiopharma

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Kalia Kumud 🔴 sold 2.0K shares of Guardant Health, Inc. (GH) at $104.60 Transaction Date: Dec 08, 2025 | Filing ID: 000010

New Form 4/A - Dominari Holdings Inc. Filed: 2025-12-10 AccNo: 0001213900-25-120286 Size: 5 KB

New Form 4/A - Dominari Holdings Inc. Filed: 2025-12-10 AccNo: 0001213900-25-120285 Size: 6 KB

MANCHESTER MANAGEMENT CO LLC 🔴 sold 144.8K shares of SANUWAVE Health, Inc. (SNWV) at $31.60 ($4.5M) Transaction Date: Dec 08, 2025 | Filing ID: 007315

New Form 3 - OPGEN INC Filed: 2025-12-10 AccNo: 0001829126-25-009873 Size: 4 KB

New Form SCHEDULE 13G/A - EXICURE, INC. Filed: 2025-12-10 AccNo: 0001013594-25-001502 Size: 11 KB

New Form SCHEDULE 13D/A - TRINITY BIOTECH PLC Filed: 2025-12-10 AccNo: 0001193125-25-314692 Size: 153 KB

SANGSANGIN INVESTMENT & SECURITIES CO., LTD. 🔴 sold 433.3K shares of EXICURE, INC. (XCUR) at $8.71 ($3.8M) Transaction Date: Dec 08, 2025 | Filing ID: 001501

Director ROTHBERG JONATHAN M 🔴 sold 945.4K shares of Butterfly Network, Inc. (BFLY) at $3.27 ($3.1M) Transaction Date: Dec 08, 2025 | Filing ID: 120080

Indivior Notification

New Form SCHEDULE 13D/A - INDIVIOR PLC Filed: 2025-12-10 AccNo: 0001011438-25-000594 Size: 70 KB

Wong Ryan Ho-Yan 🔴 sold 158 shares of Sarepta Therapeutics, Inc. (SRPT) at $20.96 Transaction Date: Dec 01, 2025 | Filing ID: 314652

Natera - Phase III PALLAS Study Shows Signatera™MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate RiskHR+/HER2‑ Breast Cancer

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer